Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.84 EUR | -0.82% | +1.89% | +56.13% |
Apr. 25 | Onward Medical N.V. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Apr. 02 | Onward Medical Seeks US FDA Nod to Market Spinal Cord Stimulation Therapy | MT |
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+57.42% | 182M | - | ||
+73.50% | 12.41B | B- | ||
-19.26% | 7.87B | C+ | ||
+2.40% | 6.37B | C- | ||
+3.66% | 5.81B | B | ||
+11.89% | 5.36B | D+ | ||
+37.45% | 4.92B | - | ||
-19.73% | 4.02B | B- | ||
-35.58% | 2.43B | C | ||
+0.74% | 2.02B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ONWD Stock
- Ratings Onward Medical N.V.